blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4070787

EP4070787 - PHARMACEUTICAL FORMULATIONS [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  27.01.2023
Database last updated on 05.10.2024
FormerGrant of patent is intended
Status updated on  02.01.2023
FormerExamination is in progress
Status updated on  16.09.2022
FormerRequest for examination was made
Status updated on  09.09.2022
Most recent event   Tooltip26.07.2024Change - opposition data/opponents data or that of the opponents representativepublished on 28.08.2024  [2024/35]
Applicant(s)For all designated states
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 / US
[2022/41]
Inventor(s)01 / KOZIARA, Joanna, M.
Foster City, 94404 / US
02 / MCCALLISTER, Scott
Foster City, 94404 / US
 [2022/41]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2022/41]
Application number, filing date22176524.129.06.2016
[2022/41]
Priority number, dateUS201562187113P30.06.2015         Original published format: US 201562187113 P
US201662298373P22.02.2016         Original published format: US 201662298373 P
US201662301429P29.02.2016         Original published format: US 201662301429 P
US201662317286P01.04.2016         Original published format: US 201662317286 P
[2022/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4070787
Date:12.10.2022
Language:EN
[2022/41]
Type: B1 Patent specification 
No.:EP4070787
Date:01.03.2023
Language:EN
[2023/09]
Search report(s)(Supplementary) European search report - dispatched on:EP29.08.2022
ClassificationIPC:A61K9/20, A61K9/24, A61K31/513, A61K31/675, A61K9/00, A61K9/28
[2022/41]
CPC:
A61K9/2054 (EP,KR,US); A61K9/0053 (EP,KR,US); A61K31/513 (EP,KR,US);
A61K31/675 (EP,KR,US); A61K9/2013 (KR,US); A61K9/209 (EP,KR,US);
A61K9/284 (KR,US); A61K9/2866 (EP,US); A61P31/18 (EP);
A61P43/00 (EP) (-)
C-Set:
A61K31/513, A61K2300/00 (EP,US);
A61K31/675, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/41]
Extension statesBA31.05.2022
ME31.05.2022
Validation statesMA31.05.2022
MD31.05.2022
TitleGerman:PHARMAZEUTISCHE FORMULIERUNGEN[2022/41]
English:PHARMACEUTICAL FORMULATIONS[2022/41]
French:FORMULATIONS PHARMACEUTIQUES[2022/41]
Examination procedure31.05.2022Examination requested  [2022/41]
29.08.2022Date on which the examining division has become responsible
15.09.2022Despatch of a communication from the examining division (Time limit: M04)
25.10.2022Reply to a communication from the examining division
03.01.2023Communication of intention to grant the patent
18.01.2023Fee for grant paid
18.01.2023Fee for publishing/printing paid
18.01.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP16739625.8  / EP3316868
EP19199257.7  / EP3607939
Opposition(s)Opponent(s)01  29.11.2023  30.11.2023  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Reddie & Grose LLP
The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
 [N/P]
Former [2024/35]
Opponent(s)01  29.11.2023  30.11.2023  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Reddie & Grose LLP
The White Chapel Building 10 Whitechapel High Street
London E1 8QS / GB
Former [2024/01]
Opponent(s)01  29.11.2023  30.11.2023  ADMISSIBLE
Zentiva, k.s.
U kabelovny 130
102 37 Praha 10 - Dolni Mecholupy / CZ
Opponent's representative
Ellis, Robin Patrick
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
13.12.2023Invitation to proprietor to file observations on the notice of opposition
12.04.2024Reply of patent proprietor to notice(s) of opposition
03.02.2025Date of oral proceedings
Fees paidRenewal fee
31.05.2022Renewal fee patent year 03
31.05.2022Renewal fee patent year 04
31.05.2022Renewal fee patent year 05
31.05.2022Renewal fee patent year 06
31.05.2022Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipDK01.03.2023
EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
MC01.03.2023
RO01.03.2023
RS01.03.2023
SM01.03.2023
LU29.06.2023
IS01.07.2023
[2024/15]
Former [2024/09]DK01.03.2023
EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
MC01.03.2023
RO01.03.2023
RS01.03.2023
SM01.03.2023
IS01.07.2023
Former [2023/50]EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
RO01.03.2023
RS01.03.2023
SM01.03.2023
IS01.07.2023
Former [2023/49]EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
RO01.03.2023
RS01.03.2023
SM01.03.2023
Former [2023/48]EE01.03.2023
FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
RS01.03.2023
SM01.03.2023
Former [2023/46]FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
RS01.03.2023
SM01.03.2023
Former [2023/36]FI01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
RS01.03.2023
Former [2023/35]HR01.03.2023
LT01.03.2023
RS01.03.2023
Former [2023/34]LT01.03.2023
RS01.03.2023
Former [2023/33]LT01.03.2023
Documents cited:Search[I]WO2013116720  (GILEAD SCIENCES INC [US]);
 [I]WO2015022351  (RATIOPHARM GMBH [DE]);
 [PA]WO2015196116  (GILEAD SCIENCES INC [US]);
by applicantWO0208241
 WO03016306
 WO2013025788
OppositionUS2007077295
 WO2013025788
 EP1583542
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.